Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Feb 21;17(1):160.
doi: 10.1186/s12879-017-2266-3.

The virological durability of first-line ART among HIV-positive adult patients in resource limited settings without virological monitoring: a retrospective analysis of DART trial data

David I Dolling  1 , Ruth L Goodall  2 , Michael Chirara  3 , James Hakim  3 , Peter Nkurunziza  4 , Paula Munderi  4 , David Eram  5 , Dinah Tumukunde  5 , Moira J Spyer  1 , Charles F Gilks  6 , Pontiano Kaleebu  4 , David T Dunn  1 , Deenan Pillay  7 ; DART Virology Group
Collaborators, Affiliations

The virological durability of first-line ART among HIV-positive adult patients in resource limited settings without virological monitoring: a retrospective analysis of DART trial data

David I Dolling et al. BMC Infect Dis. .

Abstract

Background: Few low-income countries have virological monitoring widely available. We estimated the virological durability of first-line antiretroviral therapy (ART) after five years of follow-up among adult Ugandan and Zimbabwean patients in the DART study, in which virological assays were conducted retrospectively.

Methods: DART compared clinically driven monitoring with/without routine CD4 measurement. Annual plasma viral load was measured on 1,762 patients. Analytical weights were calculated based on the inverse probability of sampling. Time to virological failure, defined as the first viral load measurement ≥200 copies/mL after 48 weeks of ART, was analysed using Kaplan-Meier plots and Cox regression models.

Results: Overall, 65% of DART trial patients were female. Patients initiated first-line ART at a median (interquartile range; IQR) age of 37 (32-42) and with a median CD4 cell count of 86 (32-140). After 240 weeks of ART, patients initiating dual-class nucleoside reverse-transcriptase inhibitor (NRTI) -non-nucleoside reverse-transcriptase (NNRTI) regimens containing nevirapine + zidovudine + lamivudine had a lower incidence of virological failure than patients on triple-NRTI regimens containing tenofovir + zidovudine + lamivudine (21% vs 40%; hazard ratio (HR) =0.48, 95% CI:0.38-0.62; p < 0.0001). In multivariate analyses, female patients (HR = 0.79, 95% CI: 0.65-0.95; p = 0.02), older patients (HR = 0.73 per 10 years, 95% CI: 0.64-0.84; p < 0.0001) and patients with a higher pre-ART CD4 cell count (HR = 0.64 per 100 cells/mm3, 95% CI: 0.54-0.75; p < 0.0001) had a lower incidence of virological failure after adjusting for adherence to ART. No difference in failure rate between the two randomised monitoring strategies was observed (p= 0.25).

Conclusions: The long-term durability of virological suppression on dual-class NRTI-NNRTI first-line ART without virological monitoring is remarkable and is enabled by high-quality clinical management and a consistent drug supply. To achieve higher rates of virological suppression viral-load-informed differentiated care may be required.

Trial registration: Prospectively registered on 18/10/2000 as ISRCTN13968779 .

Keywords: HIV-infected adults; Low-income; Resource-limited; Treatment outcomes; Virological failure.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Cumulative percentage with virological failure (viral load > 200 copies/mL) by first-line ART regimen. Figure shows cumulative percentage with virological failure estimated using the Kaplan-Meier method incorporating analytical weights. Number at risk = number of patients alive and on continuous first-line ART without virological failure
Fig. 2
Fig. 2
Cumulative percentage with virological failure (viral load > 200 copies/mL) by age at randomisation. Figure shows cumulative percentage with virological failure estimated using the Kaplan-Meier method incorporating analytical weights. Number at risk = number of patients alive and on continuous first-line ART without virological failure
See this image and copyright information in PMC

References

    1. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach, 2006 revision. Geneva: World Health Organisation; 2006. - PubMed
    1. Gilks CF, Crowley S, Ekpini R, Gove S, Perriens J, Souteyrand Y, et al. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet. 2006;368(9534):505–10. doi: 10.1016/S0140-6736(06)69158-7. - DOI - PubMed
    1. World Health Organization. Antiretroviral Therapy for HIV Infection in Adults and Adolescents. Recommendations for a Public Health Approach (2010 revision). Geneva: World Health Organization; 2010. - PubMed
    1. World Health Organization . Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: World Health Organization; 2013. - PubMed
    1. Paton N, Kityo C, Thompson J, Bagenda L, Hakim J, van Oosterhout JJ, et al. 119: impact of NRTI cross-resistance on second-line PI + NRTI therapy outcomes in africa. Seattle: Conference on Retroviruses and Opportunistic Infections (CROI); 2015.

Substances

Associated data